Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized ...
Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants ...
The sequences of siRNAs are summarized in Table S1. NSCLC cells were treated with the indicated compounds, and subsequently fixed with ice-cold TCA and stained with 0.4% SRB (w/v) solution. Cell ...
For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study First FcRn blocker to demonstrate sustained ...
Kharmagtai Maiden Ore Reserve reported with approximately 1.6Mt Cu and 4.0Moz Au, comprised of Indicated material within the pit shells in the Kharmagtai PFS, but excluding the final pit phase at ...